Biomarkers in Pulmonary Arterial Hypertension Treated With Nilotinib
This study has been withdrawn prior to enrollment.
Sponsor:
The Cleveland Clinic
Information provided by (Responsible Party):
Kewal Asosingh, Ph.D, The Cleveland Clinic
ClinicalTrials.gov Identifier:
NCT01320865
First received: March 18, 2011
Last updated: February 3, 2014
Last verified: February 2014
| Tracking Information | ||||
|---|---|---|---|---|
| First Received Date ICMJE | March 18, 2011 | |||
| Last Updated Date | February 3, 2014 | |||
| Start Date ICMJE | August 2010 | |||
| Primary Completion Date | December 2012 (final data collection date for primary outcome measure) | |||
| Current Primary Outcome Measures ICMJE |
Measuring circulating markers of Nilotinib affect [ Time Frame: within one year of the end of the study ] [ Designated as safety issue: No ] We will measure markers of mast cell activation in blood and urine before and during treatment with nilotinib. |
|||
| Original Primary Outcome Measures ICMJE | Same as current | |||
| Change History | Complete list of historical versions of study NCT01320865 on ClinicalTrials.gov Archive Site | |||
| Current Secondary Outcome Measures ICMJE |
Evaluate effect of Nilotinib on the activation of mast cells. [ Time Frame: within one year of the end of the study ] [ Designated as safety issue: No ] We will measure markers of mast cell activation in blood and urine before and during treatment with nilotinib. We will also look at the proliferation of mast cell progenitors and correlate this to clinical markers used to monitor this disease. |
|||
| Original Secondary Outcome Measures ICMJE | Same as current | |||
| Current Other Outcome Measures ICMJE | Not Provided | |||
| Original Other Outcome Measures ICMJE | Not Provided | |||
| Descriptive Information | ||||
| Brief Title ICMJE | Biomarkers in Pulmonary Arterial Hypertension Treated With Nilotinib | |||
| Official Title ICMJE | Not Provided | |||
| Brief Summary | The investigators hypothesize that bone marrow progenitor cells are mobilized into the circulation in PAH, home to the lungs and differentiate into mast cells, which promote vascular remodeling and vasoconstriction through release of renin and chymase. As a corollary to this, the investigators hypothesize that anti cKit tyrosine kinase inhibitor (TKI), nilotinib, provides clinical benefit to patients through inhibition of mast cell progenitor proliferation, mobilization and differentiation. To test this, the investigators will determine if mast cell progenitors and mast cell biomarkers are related to nilotinib clinical response. This will be an ancillary study, part of a placebo-controlled, double-blind multi center clinical trial of nilotinib in pulmonary arterial hypertension. | |||
| Detailed Description | Not Provided | |||
| Study Type ICMJE | Observational | |||
| Study Design ICMJE | Observational Model: Cohort Time Perspective: Prospective |
|||
| Target Follow-Up Duration | Not Provided | |||
| Biospecimen | Not Provided | |||
| Sampling Method | Probability Sample | |||
| Study Population | Patients diagnosed with PAH that are enrolled in the Nilotinib clinical trial. http://clinicaltrials.gov/ct2/show/NCT01179737?term=tasigna+and+pulmonary+hypertension&rank=1 | |||
| Condition ICMJE | PAH | |||
| Intervention ICMJE | Not Provided | |||
| Study Group/Cohort (s) | Subjects with PAH treated with nilotinib | |||
| Publications * |
|
|||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Withdrawn | |||
| Enrollment ICMJE | 0 | |||
| Completion Date | December 2012 | |||
| Primary Completion Date | December 2012 (final data collection date for primary outcome measure) | |||
| Eligibility Criteria ICMJE | Inclusion Criteria: This study is a substudy and subjects must be enrolled in the main trial: See Study Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH) In clinical trials. (clinical Trial ID NCT01179737) http://clinicaltrials.gov/ct2/show/NCT01179737? Exclusion Criteria: Subjects are not enrolled in the main study: See Study Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH) In clinical trials. (clinical Trial ID NCT01179737) http://clinicaltrials.gov/ct2/show/NCT01179737?term=tasigna+and+pulmonary+hypertension&rank=1 |
|||
| Gender | Both | |||
| Ages | 18 Years and older (Adult, Senior) | |||
| Accepts Healthy Volunteers | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | United States | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT01320865 | |||
| Other Study ID Numbers ICMJE | Novartis AMN-107 | |||
| Has Data Monitoring Committee | No | |||
| Plan to Share Data | Not Provided | |||
| IPD Description | Not Provided | |||
| Responsible Party | Kewal Asosingh, Ph.D, The Cleveland Clinic | |||
| Study Sponsor ICMJE | The Cleveland Clinic | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
|
|||
| Information Provided By | The Cleveland Clinic | |||
| Verification Date | February 2014 | |||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
||||